|
|
News Breaks
|
October 2, 2009
|
| 09:34 EDT |  | RGN |
| theflyonthewall.com: | RegeneRx reported on clinical studies with Thymosin beta 4 | | David Crockford, RegeneRx’s vice president for clinical and regulatory affairs presented an overview of the biological properties that support Tâ4’s near term and long term clinical applications. Mr. Crockford noted that special emphasis is being placed on the development of RGN-352 for the systemic treatment of patients with ST-elevation myocardial infarction in combination with percutaneous coronary intervention, the current standard of care in most western countries for this common type of heart attack. The goal with RGN-352 is to prevent or repair continued damage to cardiac tissue post-heart attack, when such tissue around the damaged site remains at risk. :theflyonthewall.com |
|
|
News For RGN From The Last 14 Days Check below for free stories on RGN the last two weeks.
| Sign up for a free trial to see the rest of the stories you've been missing. |
There are no results for these search parameters.
|
|
|
|
